The influence of ApoE4 on clinical progression of dementia: a meta-analysis: ApoE4 and clinical progression of dementia: a meta-analysis
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: ApoE4 is a risk factor for the development of Alzheimer's disease, and has a functional role suggesting its importance in the neuropathology of dementia. We present a meta-analysis to investigate whether ApoE4 also affects the clinical progression of dementia in terms of cognitive decline or mortality. METHODS: We searched Medline, Embase and PsychINFO from 1990 until April 2009, for case control or cohort studies which investigated the effect of ApoE4 on progression of dementia. We identified 427 studies; 17 were suitable for inclusion. In total, there were 1733 participants with dementia at baseline, of whom 975 were heterozygous or homozygous for ApoE4. RESULTS: There was no significant difference in cognitive decline (random-model effect size = 0.02; 95% C.-I.: -0.09 to 0.14; p = 0.67) or mortality (random-model pooled odds ratio = 0.74; 95% C.-I.: 0.36 to 1.53; p = 0.41) based on the presence of ApoE4. There was no significant heterogeneity between studies using cognitive decline as an outcome. In meta-regressions of cognitive decline, duration of symptoms, age, gender and frequency of participants with ApoE4 in the samples did not contribute to outcome. CONCLUSION: Different ApoE alleles do not modify the speed of clinical progression of dementia in a way that would be detectable in a sample of 1700 patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“Although there is good evidence that ApoE4 is a risk factor for Alzheimer’s disease (Bertram et al., 2007), our results suggest that ApoE4 does not speed clinical progression of dementia towards further cognitive decline (random-model effect size 0.025) or mortality (random-model pooled odds ratio…”
BackgroundInfluentialMemory and Executive Function in Aging and AD
Buckner, R. L. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.006 · Cited by 1,508
Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein
Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., Niinistö, L., Halonen, P., & Kontula, K. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511093331902 · Cited by 493 · cited 4×
“…example, if ApoE4 is associated with increased beta-amyloid deposition and neuro-fibrillary tangle formation (Chalmers et al., 2003; Nagy et al., 1995; Polvikoski et al., 1995), but not with later cognitive decline or increased mortality, what is the link between neuropathology and clinical course?”
BackgroundInfluentialNagy, Z. S., Esiri, M. M., Jobst, K. A., Johnston, C., Litchfield, S., Sim, E., & Smith, A. D. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00331-c · Cited by 250
Chalmers, K., Wilcock, G. K., & Love, S. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00457.x · Cited by 156
Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152 · cited 2×
“…(Basun et al., 1995; Frisoni et al., 1995; Dal Forno et al., 1996; Forstl et al., 1996; Holmes et al., 1996; Kurz et al., 1996; Stern et al., 1997; Craft et al., 1998; Jonker et al., 1998; Lehtovirta et al., 1998; Kanai et al., 1999; Juva et al., 2000; Kim et al., 2002; Mori et al., 2002; Hirono…”
BackgroundFrisoni, G. B., Govoni, S., Geroldi, C., Bianchetti, A., Calabresi, L., Franceschini, G., & Trabucchi, M. (1995) · Annals of Neurology · doi:10.1002/ana.410370509 · Cited by 149
Genetics of Alzheimer's disease: recent advances
Avramopoulos, D. (2009) · Genome Medicine · doi:10.1186/gm34 · Cited by 136
APOE ε4 does not predict mortality, cognitive decline, or dementia in the oldest old
Juva, K., Verkkoniemi, A., Viramo, P., Polvikoski, T., Kainulainen, K., Kontula, K., & Sulkava, R. (2000) · Neurology · doi:10.1212/wnl.54.2.412 · Cited by 108
Cited by
Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Hersi, M., Irvine, B., Gupta, P., Gomes, J., Birkett, N., & Krewski, D. (2017) · NeuroToxicology · doi:10.1016/j.neuro.2017.03.006 · Cited by 332
Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years
Hithersay, R., Startin, C. M., Hamburg, S., Mok, K. Y., Hardy, J., Fisher, E. M. C., Tybulewicz, V. L. J., Nizetic, D., & Strydom, A. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3616 · Cited by 176
Cognitive Decline in Alzheimer’s Disease Is Not Associated with APOE
Katzourou, I., Initiative, T. A. D. N., Leonenko, G., Ivanov, D., Meggy, A., Marshall, R., Sims, R., Williams, J., Holmans, P., & Escott-Price, V. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-210685 · Cited by 9
Metadata
- Authors
- Allan, C. L., & Ebmeier, K. P.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2010-09-15
- Volume
- 26
- Issue
- 5
- Pages
- 520-526
- ISSN
- 0885-6230 (ISSN-L)
- OpenAlex
- W1925510544
- Cited by
- 33
- References
- 10
- FWCI
- 0.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The influence of ApoE4 on clinical progression of dementia: a meta-analysis: ApoE4 and clinical progression of dementia: a meta-analysis. https://app.cochat.ai/papers/10.1002/gps.2559
- The paper
- Allan, C. L., & Ebmeier, K. P. (2011). The influence of ApoE4 on clinical progression of dementia: a meta-analysis: ApoE4 and clinical progression of dementia: a meta-analysis. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.2559
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.